ECFS 2020 - Optimizing pharmaceutical care in cystic fibrosis

European Cystic Fibrosis Society   149  OPTIMIZING PHARMACEUTICAL CARE IN CYSTIC FIBROSIS CF MEDICINES IN CHILDREN CHAPTER 8 References [1] Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: present and future. Clinical and Experimental Gastroenterology. 2011; 4:55-73. [2] Flume PA, Robinson KA, O’Sullivan BP, Finder JD, Vender RL, Willey-Cou- rand D-B, et al. Cystic fibrosis pulmo- nary guidelines: airway clearance ther- apies. Respir Care. 2009;54(4):522-37. [3] Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulmonol. 2010;46(3):230-8. [4] Stuart B, Lin JH, Mogayzel PJ. Early Eradication of Pseudomonas aerugi- nosa in Patients with Cystic Fibrosis. Paediatr Respir Rev. 2010;11(3):177- 84. [5] Flume PA, Van Devanter DR. State of progress in treating cystic fibrosis respiratory disease. BMC Medicine. 2012;10:88. [6] Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, et al. Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with aG551D Mutation. Am J Respir Crit Care Med. 2013;187(11):1219-25. [7] Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, et al. Tezacaftor–Ivacaftor in Resid- ual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med. 2017;377(21):2024-35. [8] Rosen BH, Evans TIA, Moll SR, Gray JS, Liang B, Sun X, et al. Infection Is Not Required for Mucoinflammatory Lung Disease in CFTR- Knockout Ferrets. Am J Respir Crit Care Med. 2018;197(10):1308-18. [9] Sun X, Yi Y, Yan Z, Rosen BH, Liang B, Winter MC, et al. In utero and post- natal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Science Translational Medicine. 2019;11(485):eaau7531. [10] Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, et al. Infection, Inflammation, and Lung Function Decline in Infants with Cystic Fibrosis. Am J Respir Crit Care Med. 2011;184(1):75-81. [11] Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, et al. Longitu- dinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol. 2003;36(3):230-40. [12] Rey E, Treluyer J-M, Pons G. Drug Disposition in Cystic Fibrosis. Clin Pharmacokinet. 1998;35(4):313-29. [13] Kearns GL, D P, Hilman BC, Wilson JT. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr. 1982;100(2):312-8. [14] Guimbellot J, Sharma J, Rowe SM. Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol. 2017;52(S48):S4-S14.